CAJ | 학술논문

目的：探讨合并代谢综合征的冠心病患者生活方式改善后其血清游离脂肪酸(FFA)水平的变化,以及治疗性生活方式对冠心病传统危险因素的影响。方法共筛选135例合并代谢综合征的冠心病患者,分为干预组(A 组,冠心病常规药物治疗+强化生活方式干预,n=97)和非干预组(B 组,冠心病常规药物治疗,n=38)。分别于入选时和随访结束时测定所有入选患者血清 FFA 水平,同时采集所有患者的体质指标进行比较。结果(1)合并代谢综合征的冠心病患者 FFA 水平与腰围和腰高比显著正相关；(2)治疗性生活方式干预后 A 组患者腰围、BMI 和 FFA 水平显著低于 B 组(P <0.05)；(3)与基线时比较,A 组患者经过平均6个月的治疗性生活方式干预后各体质指标和 FFA 水平均显著降低(P <0.05)。结论在规范的冠心病药物治疗基础上,治疗性生活方式可以降低合并代谢综合征的冠心病患者 FFA 水平并改善其体质指标。
목적：탐토합병대사종합정적관심병환자생활방식개선후기혈청유리지방산(FFA)수평적변화,이급치료성생활방식대관심병전통위험인소적영향。방법공사선135례합병대사종합정적관심병환자,분위간예조(A 조,관심병상규약물치료+강화생활방식간예,n=97)화비간예조(B 조,관심병상규약물치료,n=38)。분별우입선시화수방결속시측정소유입선환자혈청 FFA 수평,동시채집소유환자적체질지표진행비교。결과(1)합병대사종합정적관심병환자 FFA 수평여요위화요고비현저정상관；(2)치료성생활방식간예후 A 조환자요위、BMI 화 FFA 수평현저저우 B 조(P <0.05)；(3)여기선시비교,A 조환자경과평균6개월적치료성생활방식간예후각체질지표화 FFA 수평균현저강저(P <0.05)。결론재규범적관심병약물치료기출상,치료성생활방식가이강저합병대사종합정적관심병환자 FFA 수평병개선기체질지표。
Objective To investigate the level of serum free fatty acid (FFA )after improving the life style in patients with coronary heart disease complicated metabolic syndrome and the effect of therapeutic life style on traditional risk factors of coronary artery disease.Methods A total of 395 patients with coronary heart disease complicated metabolic syndrome were recruited.Pa-tients were divided into intervention group (group A,conventional drug therapy+ intensive life style intervention,n=97)and non-intervention group (group B,conventional drug therapy,n=38)according to the scores of life style.Serum free fatty acid (FFA) was determined by ELASA.The scores of life style was obtained by"life style questionnaire".Results (1)The serum FFA of pa-tients with coronary heart disease complicated metabolic syndrome were positively related to waist circumference and waist-high-ra-tio.(2)Waist circumference,BMI and FFA of group A were significantly lower than those in group B after therapeutic life style in-tervention(P <0.05).(3)Compared with the baseline,the constitution index and FFA in group A were significantly lower after 6-months therapeutic life style intervention(P <0.05).Conclusion Therapeutic life style can reduce the level of FFA and constitution index of the patients with coronary heart disease complicated metabolic syndrome.